VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

NCT03769155 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
BIOLOGICAL: VX15/2503
PROCEDURE: Surgery

Sponsor

Emory University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]